Literature DB >> 20690804

A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer.

Ping Tang1, Jianmin Wang, David G Hicks, Xi Wang, Linda Schiffhauer, Loralee McMahon, Qi Yang, Michelle Shayne, Alissa Huston, Kristin A Skinner, Jennifer Griggs, Gary Lyman.   

Abstract

Among the 77 infiltrating breast carcinomas, we found that progesterone receptor (PR) expression was inversely associated with recurrence score (RS, p < .0001). RS is also significantly associated with tubule formation, mitosis, and luminal B subtype. The equation of RS = 17.489 + 2.071 (tubal formation) + 2.926 (mitosis) -2.408 (PR) -1.061 (HER2) + 7.051 (luminal A) + 29.172 (luminal B) predicts RS with an R² of 0.65. In conclusion, PR negativity, luminal B subtype, tubal formation, and mitosis are strongly correlated with a higher RS.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20690804     DOI： 10.3109/07357907.2010.496754

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


  23 in total

1.  Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score.

Authors:  Bradley M Turner; Kristin A Skinner; Ping Tang; Mary C Jackson; Nyrie Soukiazian; Michelle Shayne; Alissa Huston; Marilyn Ling; David G Hicks
Journal:  Mod Pathol       Date:  2015-05-01       Impact factor: 7.842

2.  Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset.

Authors:  Michael R Harowicz; Timothy J Robinson; Michaela A Dinan; Ashirbani Saha; Jeffrey R Marks; P Kelly Marcom; Maciej A Mazurowski
Journal:  Breast Cancer Res Treat       Date:  2017-01-07       Impact factor: 4.872

3.  A study of association of Oncotype DX recurrence score with DCE-MRI characteristics using multivariate machine learning models.

Authors:  Ashirbani Saha; Michael R Harowicz; Weiyao Wang; Maciej A Mazurowski
Journal:  J Cancer Res Clin Oncol       Date:  2018-02-09       Impact factor: 4.553

4.  A Validated Model for Identifying Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay.

Authors:  Michele M Gage; Martin Rosman; W Charles Mylander; Erica Giblin; Hyun-Seok Kim; Leslie Cope; Christopher Umbricht; Antonio C Wolff; Lorraine Tafra
Journal:  Clin Breast Cancer       Date:  2015-04-23       Impact factor: 3.225

5.  Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer.

Authors:  Hyun-Seok Kim; Christopher B Umbricht; Peter B Illei; Ashley Cimino-Mathews; Soonweng Cho; Nivedita Chowdhury; Maria Cristina Figueroa-Magalhaes; Catherine Pesce; Stacie C Jeter; Charles Mylander; Martin Rosman; Lorraine Tafra; Bradley M Turner; David G Hicks; Tyler A Jensen; Dylan V Miller; Deborah K Armstrong; Roisin M Connolly; John H Fetting; Robert S Miller; Ben Ho Park; Vered Stearns; Kala Visvanathan; Antonio C Wolff; Leslie Cope
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

6.  Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors.

Authors:  Daniel J Farrugia; Alessandra Landmann; Li Zhu; Emilia J Diego; Ronald R Johnson; Marguerite Bonaventura; Atilla Soran; David J Dabbs; Beth Z Clark; Shannon L Puhalla; Rachel C Jankowitz; Adam M Brufsky; Barry C Lembersky; Gretchen M Ahrendt; Priscilla F McAuliffe; Rohit Bhargava
Journal:  Mod Pathol       Date:  2017-05-26       Impact factor: 7.842

7.  The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center.

Authors:  Stephane Thibodeau; Ioannis A Voutsadakis
Journal:  Eur J Breast Health       Date:  2019-07-01

8.  Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score.

Authors:  S Sahebjam; R Aloyz; D Pilavdzic; M-L Brisson; C Ferrario; N Bouganim; V Cohen; W H Miller; L C Panasci
Journal:  Br J Cancer       Date:  2011-10-04       Impact factor: 7.640

9.  The Correlation of Magee EquationsTM and Oncotype DX® Recurrence Score From Core Needle Biopsy Tissues in Predicting Response to Neoadjuvant Chemotherapy in ER+ and HER2- Breast Cancer.

Authors:  Atilla Soran; Kaori Tane; Efe Sezgin; Rohit Bhargava
Journal:  Eur J Breast Health       Date:  2020-04-01

10.  Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis.

Authors:  Molly E Klein; David J Dabbs; Yongli Shuai; Adam M Brufsky; Rachel Jankowitz; Shannon L Puhalla; Rohit Bhargava
Journal:  Mod Pathol       Date:  2013-03-15       Impact factor: 7.842
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.